Combined treatment with different HER2-targeted agents with complementary mechanisms has been widely adopted in the treatment of breast cancer and has proven to be a robust approach to prevent or delay resistance (Baselga et al., 2012; Oude Munnink et al., 2012). This evidence concerns the gene ERBB2 and breast carcinoma.